enVVeno Medical Corp
Change company Symbol lookup
Select an option...
NVNO enVVeno Medical Corp
MTBC CareCloud Inc
WRK Westrock Co
SNDX Syndax Pharmaceuticals Inc
SLAMU Slam Corp
SURYY Sumitomo Realty & Development Co Ltd
MKKGY Merck KGaA
DAC Danaos Corp
YY JOYY Inc
MGU Macquarie Global Infrastructure Total Return Fund Inc.
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

Closing Price: $4.22

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Light) Volume: 0 10-day average volume: 25,424: 0

Berkshire Hathaway Inc. Cl B Stock Rises Friday, Outperforms Market

4:41 pm ET January 14, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Berkshire Hathaway Inc. Cl B (BRKA) inched 0.89% higher to $324.13 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.08% to 4,662.85 and the Dow Jones Industrial Average falling 0.56% to 35,911.81. This was the stock's fourth consecutive day of gains. Berkshire Hathaway Inc. Cl B hit a new 52-week high, surpassing its previous peak of $323.47, which the company achieved on January 13th.

Trading volume (4.9 M) eclipsed its 50-day average volume of 4.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 14, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 14, 2022 16:41 ET (21:41 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and